NCT02620501

Brief Summary

Patients will be randomized to a placebo or study group who will receive topical lidocaine prior to EGD. Amount of medication used, recovery time, patient/endoscopist satisfaction will then be assessed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
106

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 26, 2015

Completed
5 months until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
5 months until next milestone

First Posted

Study publicly available on registry

December 3, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

December 3, 2015

Status Verified

December 1, 2015

Enrollment Period

7 months

First QC Date

January 26, 2015

Last Update Submit

December 2, 2015

Conditions

Keywords

EGDtopical lidocainerecovery timeintravenous sedation

Outcome Measures

Primary Outcomes (1)

  • Amount of sedation used

    We will record the amount of sedation used during the procedure

    60 minutes

Secondary Outcomes (2)

  • Recovery time

    120 minutes

  • Patient and physician satisfaction

    24 hours

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD

Drug: Placebo

Experimental

EXPERIMENTAL

Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD

Drug: Lidocaine

Interventions

topical lidocaine

Experimental

0.45% Normal Saline

Placebo

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • EGD alone performed by staff gastroenterologist as an outpatient
  • Between the age of 18 and 89
  • Not requiring anesthesia support or use of medications other than fentanyl and midazolam

You may not qualify if:

  • Prior history of head and neck surgery
  • Known hypersensitivity to local anesthetics, the amide type or any components of the topical lidocaine
  • Patients having interventions other than polypectomy performed
  • Pregnant or breast feeding females
  • Patients with severe liver impairment
  • Known hypersensitivity to benzodiazepine or fentanyl

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Brooke Army Medical Center

Fort Sam Houston, Texas, 78219, United States

RECRUITING

Related Publications (1)

  • Davis DE, Jones MP, Kubik CM. Topical pharyngeal anesthesia does not improve upper gastrointestinal endoscopy in conscious sedated patients. Am J Gastroenterol. 1999 Jul;94(7):1853-6. doi: 10.1111/j.1572-0241.1999.01217.x.

    PMID: 10406247BACKGROUND

MeSH Terms

Conditions

Deglutition DisordersGastroesophageal RefluxAbdominal Pain

Interventions

Lidocaine

Condition Hierarchy (Ancestors)

Esophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesPharyngeal DiseasesOtorhinolaryngologic DiseasesEsophageal Motility DisordersPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSigns and Symptoms, Digestive

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Adam M Tritsch, MD

    Brooke Army Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Gastroenterology Fellow

Study Record Dates

First Submitted

January 26, 2015

First Posted

December 3, 2015

Study Start

July 1, 2015

Primary Completion

February 1, 2016

Study Completion

May 1, 2016

Last Updated

December 3, 2015

Record last verified: 2015-12

Locations